Trends in Launch Prices and Price Increases for Self-Administered Anticancer Drugs in Medicare
This study examines trends in launch prices and price increases for anticancer therapies covered under Medicare Part D and approved from 2010 to 2024.
Authors
- Rahul Nayak (ORCID: https://orcid.org/0000-0001-6725-7634)
- Haiden A. Huskamp (ORCID: https://orcid.org/0000-0002-1860-3956)
- Stacie B. Dusetzina (ORCID: https://orcid.org/0000-0002-3907-9196)
- Nancy L. Keating (ORCID: https://orcid.org/0000-0002-8274-4681)
- Shelley A. Jazowski (ORCID: https://orcid.org/0000-0003-3467-2502)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Emory University (US)
- Vanderbilt University (US)
- Vanderbilt Health (US)
- Vanderbilt-Ingram Cancer Center
- Wake Forest University (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1001/jama.2025.6366
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00